ASCO® 2024 Insights: "TRANSFORM Study - 3-Year Follow-up Comparing Liso-Cel vs. SoC With Salvage Chemo and ASCT as 2L Treatment in R/R LBCL"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "TRANSFORM Study - 3-Year Follow-up Comparing Liso-Cel vs. SoC With Salvage Chemo and ASCT as 2L Treatment in R/R LBCL"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Manali Kamdar

0 views

June 20, 2024

Comments 0

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

06:26

ecancer

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

Feat. M. Al Malki, S. Devine

09:04

ecancer

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Mult…

Feat. X. Leleu

27:49

Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar

View All

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson